Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP

Neurology. 2003 Dec 9;61(11):1607-10. doi: 10.1212/01.wnl.0000096174.86850.7f.

Abstract

Patients with diabetes mellitus (DM) may develop chronic inflammatory demyelinating polyneuropathy (CIDP), which may be difficult to distinguish from diabetic neuropathy (DNP). Here the authors show that immunoreactivity for matrix metalloproteinase-9 on sural nerve biopsies may help to identify CIDP-DM. In a pilot study on 10 CIDP-DM patients with IV immunoglobulins and tight glycemic control, the CIDP-DM patients had a better outcome than DNP patients treated with tight glycemic control only.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Diabetes Complications*
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / drug therapy
  • Diabetic Neuropathies / diagnosis
  • Diagnosis, Differential
  • Female
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Male
  • Matrix Metalloproteinase 9 / analysis*
  • Matrix Metalloproteinase 9 / immunology
  • Middle Aged
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / complications
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / diagnosis*
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / drug therapy
  • Sural Nerve / enzymology*
  • Sural Nerve / pathology

Substances

  • Matrix Metalloproteinase 9